Liminatus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard

On September 24, 2026, Nasdaq notified the company that it had regained compliance with the Nasdaq Capital Market minimum bid price rule after a 1-for-50 reverse split and a transfer to the Nasdaq Capital Market on August 4, 2026. The company had previously received a notice on January 15, 2026, fo…